Rare diseases imatinib mesylate Initial PBS authority application Supporting information form (PB107)

For initial Pharmaceutical Benefits Scheme (PBS) subsidised treatment of patients with Dermatofibrosarcoma protuberans, Hypereosinophilic syndrome or chronic eosinophilic leukaemia, Platelet-Derived Growth Factor Receptor (PDGFR) B fusion gene-positive myelodysplastic or myeloproliferative disorder, Aggressive systemic mastocytosis with eosinophilia.


Page last updated: 5 February 2016

This information was printed Friday 30 September 2016 from humanservices.gov.au/health-professionals/forms/pb107 It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.